ClinicalTrials.gg
CompletedNCT03460301OPENKUpdated Jan 27, 2025

Observational of PNH Type Cells in Korean Patients With Bone Marrow Failure Syndrome and Having Hemolytic PNH

An observational study in PNH, sponsored by Handok Inc.. Completed. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-01-27.

Sponsored by Handok Inc. · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
233
Ages
19 Years and older
Sex
All
01

Study summary

Patients who are positive of PNH-type cells are followed up for the percentage of PNH-type cells regularly for examining how it change.

02

Conditions studied

  • PNH
03

In context

Lead sponsor

Handok Inc. is the lead sponsor of 46 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Idiopatic AA/MDS/Patients who had PNH clone size \<10%

Inclusion criteria

  • Patients with Commbs' test - negative
  • Any patients meeting any of Idiopathic AA/MDS/Patients who had PNH clone size \<10%

Exclusion criteria

Exclusion Criteria:

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
233 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Time-course changes in the percentage of PNH-type cells in patients who are positive of PNH-type cells during period

    Time frame: 5 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2015 to primary completion in Aug 2020, 64 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2018
First posted
Mar 9, 2018
StartActual
Mar 24, 2015
Primary completionActual
Aug 12, 2020
CompletionActual
Aug 12, 2020
Last update
Jan 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03460301
Lead sponsor
Handok Inc.
Responsible party
Sponsor
First posted
Mar 9, 2018
Start date
Mar 24, 2015
Primary completion
Aug 12, 2020
Completion
Aug 12, 2020
Last update
Jan 27, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion